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GRACE scoreUndifferentiated chest pain is one of the most common reasons for emergency department attendance and ad-
mission to hospitals. Non-ST elevation acute coronary syndrome (NSTE-ACS) is an important cause of chest
pain, and accurate diagnosis and risk stratiﬁcation in the emergency department must be a clinical priority. In
the future, the incidence of NSTE-ACS will rise further as higher sensitivity troponin assays are implemented in
clinical practice. In this article, we review contemporary approaches for the diagnosis and risk stratiﬁcation of
NSTE-ACS during emergency care. We consider the limitations of current practices and potential improvements.
Clinical guidelines recommend an early invasive strategy in higher risk NSTE-ACS. The Global Registry of Acute
Coronary Events (GRACE) risk score is a validated risk stratiﬁcation tool which has incremental prognostic
value for risk stratiﬁcation comparedwith clinical assessment or troponin testing alone. In emergencymedicine,
there has been a limited adoption of theGRACE score in some countries (e.g. UnitedKingdom), in part related to a
delay in obtaining timely blood biochemistry results. Agemakes an exponential contribution to the GRACE score,
and on an individual patient basis, the risk of younger patients with a ﬂow-limiting culprit coronary artery lesion
may be underestimated. The future incorporation of novel cardiac biomarkers into this diagnostic pathwaymay
allow for earlier treatment stratiﬁcation. The cost-effectiveness of the new diagnostic pathways based on high-
sensitivity troponin and copeptin must also be established. Finally, diagnostic tests and risk scores may optimize
patient care but they cannot replace patient-focused good clinical judgment.
© 2015 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chest pain is a very common reason to attend the emergency depart-
ment. Acute coronary syndrome (ACS) is a frequent cause of chest pain
and ACS is associated with both a short, and a longer-term adverse
prognosis.
The diagnosis of a non-ST elevationACS (NSTE-ACS) in the emergen-
cy department should be followed by risk stratiﬁcation and treatment.
In this review article, we focus on clinical guideline recommendations
for risk stratiﬁcation and the challenges relating to the implementation
of these guidelines in every day clinical practice. New developments
and potential solutions are considered.ar Research Centre, Institute of
lasgow, 126 University Place,
is an open access article under the C2. Background
Hospital attendances and admissions for acute chest pain present a
substantial burden, accounting for 5% of all emergency department at-
tendances, and 40% of acute medical admissions [1,2]. Waiting times
are a pressing societal problem and efﬁcient treatment pathways are
essential to ensure the accurate, timely and cost-effective earlymanage-
ment of NSTE-ACS patients [3]. Conversely, missed diagnoses and treat-
ment inefﬁciencies are associated with increased morbidity, mortality
and costs [4].
ACS includes unstable angina (UA), non-ST elevation myocardial
infarction (NSTEMI), and ST elevation myocardial infarction (STEMI)
[5]. The diagnosis of ACS is based on the history of ischemic symptoms
e.g. chest pain at rest, ischemic ECG changes, and elevated cardiac bio-
markers, of which cardiac troponin (cTn) is the most commonly used.
ACS has diverse causes, and the diagnosis of MI is classiﬁed according
to the underlying cause [6] (Table 1).
In contrast to evidence-based emergency provision of reperfusion
therapy in STEMI [7], the treatment pathway for non-ST elevation ACS
(NSTE-ACS) is more diverse. This heterogeneity includes variations inC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Classiﬁcation of Myocardial Infarction.
Type 1
Spontaneous MI secondary to atherosclerotic plaque rupture
Type 2
MI secondary to ischaemic imbalance
Type 3
MI resulting in death when biomarker values are unavailable
Type 4a
MI related to percutaneous coronary intervention
Type 4b
MI related to stent thrombosis
Type 5
MI related to coronary artery bypass grafting
132 D. Corcoran et al. / IJC Heart & Vasculature 8 (2015) 131–137the levels of demand (e.g. absolute number of hospital admissions) and
provision of treatment. Healthcare provision varies according to local
resource availability (staff, beds, access to cardiac catheter laboratories),
clinical guidelines (e.g. SIGN [8] andNICE [5] differ on deﬁnitions of clin-
ical risk), and in their implementation (i.e. triage to cardiology or gener-
al medical wards). NSTE-ACS patients are also a diverse patient group,
making them more challenging to diagnose and treat. Compared with
STEMI, NSTE-ACS patients tend to be older and have more co-
morbidity. Frailty and socio-economic problems are also important con-
siderations [9].3. Risk assessment of established or suspected NSTE-ACS
3.1. What the guidelines say
International [10] and national [5] guidelines emphasize urgent
invasivemanagement of higher risk patients, such as deﬁned by a Glob-
al Registry of Acute Coronary Events (GRACE) score for death or MI at 6
months greater than 140, on-going ischemia and/or hemodynamic
instability, with early (b24 h) or immediate invasive management
[Fig. 1].Fig. 1. ESC rapid rule-out of AC
With permission of the Oxford3.2. Clinical diagnosis
Initial risk assessment is made clinically, based on the history, risk
factors for coronary artery disease, clinical assessment (including the
heart rate and blood pressure) [11,12]. The ECG is recommended by
the clinical guidelines as a ﬁrst-line test that should be performed im-
mediately. The ECG has good speciﬁcity (97%), but poor sensitivity
(28%) in ACS [13]. This assessment is of pivotal importance since cardiac
biomarkers are usually unavailable initially.3.3. Biomarkers
Since their introduction over 20 years ago, cTn assays have become
the established investigation for the detection of myocardial necrosis
in the work-up of patients with suspected NSTE-ACS [14]. The assays
used have become increasingly more sensitive for the diagnosis of MI
[15]. Despite this, biomarkers other than cTn have been investigated.
The ideal cardiac biomarker would be present only in myocytes, be re-
leased early after necrosis, have a value proportional to the myocardial
infarct size, and be detectable for a number of days with a predictable
clearance [16,17]. It should be practical for use in the emergency depart-
ment and cost-effective [18].
The emergence of high-sensitivity troponin (hs-cTn) assays is an
important advance for diagnostic testing for ACS. Other potential
biomarkers include heart-type fatty acid-binding protein (H-FABP);
biomarkers of systemic inﬂammation such as CRP; markers of LV
dysfunction, namely brain natriuretic peptide (BNP); and copeptin
and ischemia-modiﬁed albumin [19].
A new biomarker in NSTE-ACS should have incremental diagnostic
and prognostic value, and be cost-effective. Their role may be to im-
prove upon the poor early sensitivity of cTn and in the further risk strat-
iﬁcation of patients with a negative second cTn. The combination of cTn
and copeptin could potentially reduce inappropriate admission to hos-
pitals [20], and novel biomarkers may improve risk stratiﬁcation of
cTn-negative patients [21]. So far, testing of novel biomarkers at presen-
tation increases sensitivity at the expense of reduced speciﬁcity. Still, aS with hs-cTn algorithm.
University Press (UK)© European Society of Cardiology, www.escardio.org/guidelines.
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on clinical grounds to help clinicians explain the origin of a patient's
symptoms [22]. The combination of hs-cTn and novel biomarkers has
also been investigated. In a prospective observational study of 478
patients, the combination of hs-cTn and copeptin demonstrated signiﬁ-
cantly higher sensitivity to identify NSTE-ACS than a repeat hs-cTn [23].
3.4. High-sensitivity cardiac troponin
hs-cTn assays are deﬁned as having an imprecision at the 99th
centile ≤10%, and cTn concentrations below the 99th centile can be de-
tected in ≥95% of normal individuals. Troponin levels as low as 3 ng/L
may nowbedetected compared to 0.05 μg/L for the third-generation as-
says [24]. A clinical strategy based on hs-cTn testing in the emergency
department will increase the detection rate for NSTEMI, and potentially
enable the earlier use of evidence-based therapies to prevent ischemic
complications. Such a strategy might also facilitate earlier stress testing
or discharge of patients from the emergency department [25,26].
Based on increased sensitivity, hospital admission for a 12h cTn
should generally not be required, but a second test might be reliable
at 6h leading to a sensitivity of 99–100% [6]. The optimal timing of a sec-
ond test will most likely be related to the initial likelihood of coronary
disease based on clinical characteristics, and future population-level
studies will be needed to work this out. Serial sampling and a rising
hs-cTn concentration, or a ‘delta value’ of 20%, may improve speciﬁcity
[10], and hs-cTn may add incremental value to the discrimination of
the GRACE score [27]. The current European Society of Cardiology
(ESC) consensus guideline on the use of hs-cTn recommends that for
patients with a negative initial hs-cTn or values close to the upper refer-
ence limit URL, a 50% delta value or an absolute increase of 7 ng/L at 3 h
can be used to diagnose MI. In patients with elevated hs-cTn at presen-
tation, a delta value of 20% at 3 h can be used [28]. Overall, the increase
in sensitivity of the diagnostic tests will inevitably contribute to
increases in the detection and incidence of NSTEMI [29,30].
Unfortunately, with the increased sensitivity there is a reduction in
speciﬁcity, with a reported value of 80–85% leading to higher false-
positive values [31]. hs-cTn is speciﬁc for myocardial injury but not
ACS. Low-level detectable troponin may be present due to chronic kid-
ney disease, supposed stable coronary artery disease or even exercise-
induced transient ischemia. cTn release may also be secondary to
other conditions such as pulmonary thrombo-embolism or myocardial
oxygen-perfusionmismatch leading to a Type 2MI (e.g. newonset atrial
ﬁbrillationwith an uncontrolled ventricular rate) [32]. Such increases in
hs-cTn should not be interpreted as clinically insigniﬁcant. In a recent
cohort study of consecutive patients admitted to an acute medical unit
over one month, 564 patients had hs-cTn measured on admission,
representing approximately 50% of all admissions. Of those who had
hs-cTn measured, 40% had a result N14 ng/l, but only 20% had a ﬁnal
diagnosis of MI. In spite of this, mortality was 31% at one year, with a
tendency towards worse outcome in those with a ﬁnal diagnosis other
than MI [33].
3.5. Novel biomarkers
3.5.1. Copeptin
Copeptin is the C-terminal part of the arginine vasopressin (AVP)
precursor. Copeptin is a surrogate marker for AVP, which is elevated
in NSTE-ACS, but whose utility is limited by a short half-life. It is postu-
lated that AVP is released as part of the endocrine stress axis response to
ACS. Copeptin levels rise rapidly at 0–4h and decline over 2–5 days. A
copeptin assay was subject to a NICE medical technology guidance re-
port which recommended that further clinical studies were required
to assess its utility. In the largest trial to date in 2013, copeptin testing
facilitated the exclusion of NSTEMIwithin 4h of attendance at the emer-
gency department [34]. The combination of a negative copeptin and a
negative troponin increased the negative predictive value to 99% [35],which may help to reduce the time taken to rule out myocardial
infarction if introduced into clinical practice.
3.6. H-FABP
H-FABP is an intracellular protein involved in myocardial fatty acid
metabolism, but is also expressed in lower levels in other tissues [36].
It is rapidly detectable following myocardial ischemia and infarction,
but has not been shown to have incremental diagnostic value in the
diagnosis of MI when combined with hs-cTn [37].
3.7. Cost-effectiveness
The cost-effectiveness of new biomarkers in the ACS diagnostic
pathway is paramount, as highlighted by theHealth Technology Assess-
ment for the National Institute for Health Research (NIHR) [21]. As
would be expected, admission for a second cTn level was not found to
be cost-effective unless it could be acted upon rapidly when compared
with hs-cTn testing on presentation and a second level at 3h. The latter
strategy could facilitate the early discharge of patients from the emer-
gency department prior to the 4h target.
Regarding novel biomarker testing at presentation, the addition of
H-FABP, copeptin and myoglobin demonstrated increased sensitivity
at an acceptable QALY threshold, but more evidence is needed.
3.8. Risk scores
3.8.1. Current approaches and challenges with initial risk stratiﬁcation
Risk estimation by physicians on clinical grounds alone correlates
poorly with observed outcomes [38]. Despite being associated with
poorer prognosis, troponin per se is not an accurate measure of risk
when compared to risk scores which incorporate clinical variables, the
ECG, and biomarkers [39].
Once a diagnosis of NSTE-ACS is suspected and/or conﬁrmed, clinical
guidelines recommend risk stratiﬁcationwith the GRACE score [5,10]. It
was derived from a large registry of ACS patients (n = 11,389) to pre-
dict death and death or MI in-hospital and at six months [40,41,42].
The web-based calculator (or ‘app’) is simple to use and the result is
expressed as a probability (%) value or a score.
In order to complete the GRACE score, blood chemistry results are
needed, which take time to obtain during clinical care, especially if
paired tests are performed, separated by a 12h interval. This delay
means that NSTE-ACS patients are normally admitted to the hospital,
at least temporarily.
3.9. GRACE score
GRACE 1.0 score has been extensively validated [10]. GRACE 1.0
predicts the in-hospital and 6-month risk of death or MI using the var-
iables: age, heart rate, systolic blood pressure, creatinine, Killip classiﬁ-
cation of heart failure, ST-segment deviation, elevated cTn, and the
occurrence of cardiac arrest on admission. The ESC and NICE guidelines
recommend using this score to identify those patients who will beneﬁt
from an invasive strategy. The recently implemented GRACE 2.0 score
implements revised GRACE algorithms for predicting death and death
orMI at 1 and 3 years, and is now deﬁned as amedical device (available
at http://www.gracescore.org/WebSite/WebVersion.aspx).
3.10. Limitations of the GRACE score
3.10.1. Partial adoption
The GRACE risk score is only partially used in real-life clinical prac-
tice [43]. In an audit conducted in our hospital in Glasgow over a four-
month period in 2011, only 34.5% of all patients (n = 55) referred
from the emergency department with a diagnosis of ACS had a GRACE
score calculated and recorded in the case notes (unpublished data).
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proforma, further audit indicates that adoption has not changed. Peer
feedback from cardiologists in other European hospitals also indicates
partial adoption. Suboptimal risk stratiﬁcation in the emergency depart-
mentmay lead to non-evidence-based treatment decisions and transfer
to inappropriate wards.
The reasons for non-adoption of theGRACE score in daily practice in-
clude a lack of awareness bymedical and nursing staff, a lack of access to
the on-line website, and lack of time in a busy department since the
creatinine and troponin blood results are required before the score
can be completed. One other limitation could be that the GRACE tool
has different numeric outputs, as a percentage risk and a score, which
may lead to user uncertainty. A recent qualitative study of health prac-
titioners at 11 hospitals throughout The Netherlands on the use of risk
scores highlighted similar issues [44].
Some solutions to these problems include education of medical and
nursing staff in the emergency department, the GRACE score ‘app’ for
handheld devices, bookmarked access to the GRACE website, and also
hospital admission documentswhich require theGRACE score to enable
appropriate in-patient stratiﬁcation.
The Myocardial Ischaemia National Audit Project (MINAP) registry
of patients admitted in England and Wales with ACS collects six of the
eight variables of the GRACE score. To assess the performance of the
GRACE score in the MINAP registry, NICE produced a ‘mini-GRACE’
score to allow the calculation of a GRACE risk score without themissing
variables (a creatinine value or Killip class). This scorewas subsequently
modiﬁed to produce the ‘adjusted’ mini-GRACE score using the MINAP
variables ‘creatinine above 200 or not’, and ‘loop diuretics prescribed
during admission’ as surrogates for creatinine and Killip class [45].
This is available online as the ‘GRACE 2.0 Risk Calculator’, and allows
risk stratiﬁcation without a creatinine, but there is still a need to wait
for the cTn value. This score correlateswell in theNICE analysis, but per-
formed less well in the highest risk patients.
3.10.2. Limitations with accuracy
Age has an exponential contribution to the GRACE score. For exam-
ple, a young cigarette smoker (e.g. 35 year old male) without ischemic
ECG changes or other abnormalities but with an elevated troponin con-
centrationmay still have a relatively lowGRACE score (e.g. 87 for death/
MI at 6 months). Alternatively, an elderly person with a troponin eleva-
tion and non-speciﬁcﬁxed ECG changeswill have a GRACE score greater
than 140. According to clinical guidelines from NICE, the younger pa-
tient would be managed medically whereas the older patient could be
referred for urgent invasive angiography. Clearly, clinical judgment is
important [46]. Finally, chest pain patients with suspected but un-
conﬁrmed ACS may be unnecessarily exposed to the risks of anti-
thrombotic drug therapies, especially if the ﬁnal diagnosis is a non-
ischemic etiology.
3.11. TIMI and PURSUIT scores
The TIMI [47] and PURSUIT [48] risk scores have also been widely
validated, but GRACE has superior discriminative value for prognostica-
tion [5].
3.12. Treatment of suspected rather than conﬁrmed NSTE-ACS
Clinical guidelines recommend prescription of evidence-based anti-
thrombotic therapies including aspirin, a P2Y12 inhibitor, and anti-
coagulation when an ACS appears likely [10]. Conversely, there is a
bleeding risk associatedwith these drugs,meaning the initial risk–beneﬁt
ratio in low risk NSTE-ACS patients is less clear. Bleeding complications in
NSTE-ACS are associated with a poorer prognosis and bleeding scores
have been developed to help inform the likelihood of bleeding [10].
However, bleeding risk scores are infrequently used in daily practice.Audit data in our hospital indicates that dual anti-platelet therapy
including ticagrelor has been administered at the time of the ﬁrst med-
ical contact in patients with suspected but unconﬁrmed NSTE-ACS, and
in some of these patients the ﬁnal diagnosis was non-cardiac. Since an
expectant approach to prescription of triple anti-thrombotic therapy
could expose patients to unnecessary bleeding complications (especial-
ly in the elderly) and incur sub-optimal use of secondary care resources
(i.e. morbidity related to bleeding complications), our practice now re-
stricts P2Y12 inhibitor therapy to patients with a conﬁrmed ACS.
3.13. Bleeding scores
Major bleeding in ACS is associatedwithworse outcome [49]. Bleed-
ing scores have a class 1B recommendation in the ESC guidelines, how-
ever they are rarely used in clinical practice. The intention is that these
scores will predict the baseline bleeding risk, which can be interpreted
togetherwith a risk stratiﬁcation score such asGRACE, in order to deﬁne
a patient's treatment strategy and the anti-thrombotic therapies
prescribed.
The most frequently used is the CRUSADE bleeding score which as-
signs patient a number of points from 1 to 100 based on 8 independent
predictors of major in-hospital bleeding [50]. This score was subse-
quently validated in 17,857 patients admitted with NSTE-ACS [51]. An
online calculator is available at http://www.crusadebleedingscore.org.
With the introduction of the newer P2Y12 inhibitors, the increasing
use of the novel oral anti-coagulants, and the development of agents
such as the PAR-1 agonists, bleeding risk assessment will continue to
evolve.
3.14. Problems with diagnostic tests
In order to facilitate the clinically-appropriate rapid discharge
from the emergency department of patients who present with
low-intermediate risk chest pain, and conversely to triage appropri-
ate NSTE-ACS patients to Cardiology beds, stress and non-invasive
imaging modalities have been evaluated in the acute setting. A
signiﬁcant regional variation in their use exists depending on local
expertise and availability.
3.15. Exercise treadmill testing
Clinical guidelines do not recommend routine exercise treadmill
testing (ETT) for risk stratiﬁcation of NSTE-ACS patients. However, clin-
ical practice often differs from guidelines, and treadmill exercise testing
is still widely used in some countries, including the United Kingdom.
This is especially true in hospitals with high admission rates, limited
bed capacity, and where demand for invasive angiography exceeds ca-
pacity. Clinicians may use the treadmill test to facilitate the discharge
of low-intermediate risk medically stabilized NSTE-ACS patients [8].
3.16. CT coronary angiography
CTCA has been proposed as amodality to improve the earlymanage-
ment of NSTE-ACS patients. In the largest study to date, involving 1000
patients at 9 hospitals in the United States, CTCA facilitated the exclu-
sion of a diagnosis of ACS, increasing discharge from the emergency de-
partment and reducing length of stay [52]. This study was performed
during normal working hours, and widespread adoption of CTCA
could be limited by lack of availability out-with ofﬁce hours. Alterna-
tively, a diagnostic pathway based on CTCAmight in fact necessitate po-
tentially unnecessary admissions to hospital if out-of-hours imaging is
not available. CTCA involves exposure to ionizing radiation which may
be minimized by dose-limiting techniques such as prospective gating.
However, in reality, high heart rate and rhythm variations often pre-
clude prospective gating or other measures to reduce radiation expo-
sure (e.g. padding) such that a retrospective approach with higher
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radiation exposure that is at least as high as invasive angiography.
Finally, although CTCA has high negative predictive value, the positive
predictive value is inferior to invasive angiography. CTCA is not
evidence-based for risk stratiﬁcation of NSTE-ACS. However, its non-
evidence based use for this purpose in every-day practice in some hos-
pitals (especially hospitals without invasive angiography) should be a
matter of some concern.
For the heterogeneous population of troponin-negative patients,
there is some evidence that non-invasive CTCA coronary angiography
(CTCA) in a selected populationwith a higher underlying risk of adverse
events may be cost-effective. One proposed strategy is the stratiﬁcation
of troponin-negative patients with novel biomarker testing, with those
at higher risk undergoing CTCA [21].
3.17. Stress imaging
In contrast to anatomical non-invasive imaging, functional stress im-
aging has also been investigated to aid diagnosis and risk stratify pa-
tients presenting acutely with chest pain suspicious of ACS, but who
are troponin-negative and do not have diagnostic ECG ﬁndings.
Stress echocardiography has previously been shown to be superior
to ETT in the risk stratiﬁcation of patients presenting acutely with
chest pain [53]. In the largest study to date, 839 consecutive patients
whohad a non-diagnostic ECG and negative 12h cTnwere risk stratiﬁed
with exercise of dobutamine stress echocardiography. Rapid discharge
and accurate risk stratiﬁcation were demonstrated for this modality in
a chest pain unit setting [54]. As with CTCA, this study was performed
within working hours, meaning that patients admitted over the week-
end had a longer length of stay.
Single photon emission computed tomography (SPECT) has also
been validated in the acute chest pain setting using rest-only and
stress-only protocols [55,56]. However, as with CTCA, ionizing radiation
is required, and availability is limited for the high throughput of patients
required to facilitate discharge from the ED. Similarly, stress perfusion
cardiac MRI is limited by availability and high initial cost in this setting,
but has been demonstrated to be feasible and effective at reducing ad-
missions [57].
3.18. Stratiﬁcation to invasive management
Clinical guidelines recommend risk stratiﬁcation of NSTE-ACS pa-
tients with the GRACE score once the diagnosis has been established.
The ESC guidelines recommend that patients with a GRACE of greater
than 140 should undergo coronary angiography within 24h [10], andFig. 2. ESC decision-maki
With permission of the O
guidelines.for very high risk patients the angiogram should be performed within
2h. Patients with NSTE-ACS who are assessed as lower risk (e.g.
GRACE score b 140) invasive management should be performed within
72h. [Fig. 2].
NICE [5] recommends that patients with an intermediate risk
(GRACE scores 88–100, representing a 6-month mortality N3.0%) or
higher should be triaged for an invasive strategy, with coronary angiog-
raphyperformedwithin 96hwith follow-on PCI or CABGas appropriate.
Medically stabilized lower risk patients (e.g. GRACE score b 88 as per the
NICE guidelines) may be discharged with planned outpatient angiogra-
phy, as clinically appropriate [5].
A meta-analysis of three large trials investigating a routine invasive
versus selective invasive strategy in patients with NSTE-ACS namely
FRISC, RITA-3, and ICTUS, which themselves had shown conﬂicting re-
sults, demonstrated beneﬁt of a routine invasive strategy, driven pre-
dominantly by a reduction in MI. The largest beneﬁt was seen in those
at highest risk, deﬁned by the GRACE score [58]. The TIMACS trial,
which compared an early (within 24h), with a delayed (minimum of
36h) invasive strategy did not show a beneﬁt of routine early coronary
angiography within 24h, except within the subgroup of patients with a
GRACE risk score at admission for death or MI at 6 months of greater
than 140, who were deemed high risk [59]. This trial result supports
the stratiﬁcation of treatment based on the GRACE score, although the
evidence-base is limited. It should be remembered however that the
GRACE scorewas developed to predict in-hospital and 6-monthmortal-
ity, and not the utility of undergoing invasive management.3.19. Delays to coronary angiography
In practice, achieving invasivemanagementwithin the recommend-
ed timelines is difﬁcult, as indicated by the British Cardiovascular Inter-
vention Society National Audit (2012) [60]. Overall, 65.9% of patients
referred for early invasive management had coronary angiography
performed within 96h. For patients initially admitted to a non-
interventional hospital and who require inter-hospital transfer to a ter-
tiary centre for coronary angiography, the average time to angiography
was 104.7h, which is nearly double the time-to-angiography for
patients admitted to a hospital with interventional cardiology on site
(63.8h) [Fig. 3].
In contrast to the widespread 24/7 availability of primary PCI for
STEMI patients, provision of invasive management for higher risk
NSTEMI patients varies widely. Some European hospitals transfer
NSTEMI urgently to the catheter laboratory in just a few hours in line
with clinical guidelines whereas many hospitals e.g. in the United
Kingdom, provide a routine ofﬁce hour service. As such, a patient whong algorithm in ACS.
xford University Press (UK)© European Society of Cardiology, www.escardio.org/
Fig. 3. Delay to PCI in those patients admittedly directly to an interventional hospital
compared with those requiring inter-hospital transfer (IHT). BCIS Audit Returns 2012.
Reprint permission granted from Dr. Peter Ludman, Consultant Cardiologist, Queen
Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK; peter.ludman@uhb.nhs.uk.
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lized symptomsmaywait until the followingweek for coronary angiog-
raphy. A retrospective study of 1190 patients admitted with ACS in
Edinburgh demonstrated that patients waited longer for in-patient cor-
onary angiography (2.7 vs. 2.0 days) if they were admitted to a district
general hospitalwith no on-site cardiac catheterization laboratory com-
pared with admission to an interventional center [61]. A similar delay
was demonstrated in an audit undertaken in New Zealand in 2010,
with a longer median wait (5.1 vs. 2.5 days) for patients admitted to a
non-interventional hospital [62].
4. Conclusion
The clinical and health economic utility of non-invasive imaging in a
population with suspected ischemic chest pain in routine hospital prac-
tice has been called into question [63] and the value of physician discre-
tion in decision making has again been emphasized [64]. There can be
no substitute for good clinical judgment, based on the acquired diagnos-
tic skills, knowledge of the literature, and clinical experience. Risk scores
and tests may complement but not replace patient-focused treatment
decisions by the emergency medicine staff.
The optimal risk stratiﬁcation of NSTE-ACS patients is a key priority
in emergency medicine. Risk stratiﬁcation based on prognostic scoring,
such as GRACE, improves the selection of higher-risk patients for inva-
sive management. However, the accuracy of diagnostic strategies is
key to preventing inappropriate hospital admissions, minimizing avoid-
able morbidity and costs. The role for novel biomarkers in addition to
cTn has yet to be established, but may help to deﬁne those who are
truly low risk and who can be safely discharged from the ED. Given
their limitations, these toolswill assist but not replace clinical judgment.
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